Alibaba Group vs Davita Inc — how do they compare? Alibaba Group trades at $118.78 (market cap $270.70B), while Davita Inc trades at $232.01 (market cap $15.12B). The key difference: Alibaba Group is far larger — about 17.9× Davita Inc's market cap, and Alibaba Group pays a 0.93% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| BABA | DVA | |
|---|---|---|
Market Cap | $270.70B | $15.12B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $235.71 |
52-Week Low | $94.83 | $103.87 |
Enterprise Value | $265.53B | $27.67B |
Dividend Yield | 0.93% | — |
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $112.35, up 0.02% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with robust fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 17.36 appear reasonable. The stock faces headwinds from securities investigations but benefits from AI-driven optimism in cloud growth.
Outlook remains positive given Wall Street's $195 price target and 86% buy ratings, though risks include legal overhangs and earnings volatility. AI and cloud initiatives offer growth catalysts, but investors should monitor regulatory developments and quarterly execution against expectations.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →